ProQinase enters integrated drug discovery partnership for new AML drug

02-Feb-2020

ProQinase has signed a multi-year agreement for an integrated drug discovery project together with South Korea-based Bionetix and Netherlands-based MercachemSyncom. The project encompasses all steps from target identification up to clinical candidate selection on an undisclosed target aimed at acute myeloid leukemia (AML).

ProQinase, the European subsidiary of Reaction Biology, will perform biochemical, cell-based, and animal testing, while MercachemSyncom will contribute medicinal chemistry work.

The goal is to advance the project to the clinical phase by 2023.

Read the press release here.